BioSenic SA — Governance Information 2017

Apr 26, 2017

THOMAS LIENARD MBA – Chief Executive Officer

Thomas Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry.

Prior to joining Bone Therapeutics, Thomas Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, he worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Thomas Lienard started his career in 1999 as consultant at McKinsey & Company. He graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004.

Thomas Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed CEO in October 2016.

Damian MARRON

Profile

Damian Marron is an experienced life sciences executive with a successful track record of value creation in public and private biotechnology companies through public, VC and non-dilutive financing (including IPO), sale to large cap pharma, biotech M&A and corporate turnaround.

He's a highly accomplished leader focused on strategic and portfolio planning, company development and deal making.

He has achieved deals with top ten pharma through to biotechs including M&A, license agreements, research collaborations and marketing agreements.

Damian Marron has a broad background in the pharmaceutical industry from basic research and clinical development through to sales and strategic marketing allied to scientific training giving the breadth of view required to operate successfully at the highest level in and around the biotechnology and life sciences arena. He possesses an extensive network of contacts globally from big pharma through to biotech companies and with investors, banks and analysts.

Experience

2015 - 2017 CEO and Director Agalimmune Ltd and EIR Animatrix Capital

2013 - 2015 CEO and Director, TxCell SA, France

2012 - 2013 CEO and Director, Cytheris SA, France

2008 - 2012 CEO and Director, Trophos SA, France

2002 - 2008 Executive VP Corporate Development, NicOx SA, France

Previously (1986-2002) senior and operational roles at 3M Health Care, Orphan Europe, Chügai-Rhône Poulenc JV, Rhône Poulenc-Rorer SA, Glaxo, Coralab and the University of Liverpool.

STEVEN SWINSON

Profile

Dr. Steve Swinson is a senior executive with international experience in the health care sector, especially in the area of medical device technology and capital equipment. A PhD in engineering obtained in the UK and a US MBA degree combined with his professional international experience across Europe, Asia and the Americas allow him to relate to a broad spectrum of business areas, such as, strategy, sales, marketing, R&D, finance, supply chain, market access, business development, reimbursement, clinical and general management.

Experience

Medtronic International, Tolochenaz, Switzerland:
2011–2014	Vice President, Spine & Biologics Europe and Canada
2011	Vice President and General Manager Spine Int.
2009	Vice President Spine & Surgical Technologies Europe
2008	Regional Vice President, Europe
2005	Vice President, Emerging Markets
2003	Vice President, Spine, ENT and SNT

General Electric, USA:

2002	Global Diagnostic X-Ray General Manager
2000	VP and General Manager Americas Commercial Operations

Previously senior roles at Marquette Medical Systems Hong Kong (1997), Hewlett Packard (1989 – 1995) and Schlumberger Africa (1981-1985)

Current mandates:

Member of the board of KB Medical SA (Switzerland) Chairman of the board of Vexim SA (France)